contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  availableLanguages
  pageUrl
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


cyxone-ab-publishes-outcome-of-rights-issue

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

availableLanguages

pageUrl

imgUrl

description

Cyxone is a biotechnology company. The company's specialist expertise is found in the development of pharmaceuticals with a focus on plant protein as a base. The pharmaceutical is intended to be used mainly in the treatment of immune-related diseases, and the products are based on cyclotide technology. The purpose is that the pharmaceutical will be used in the treatment of multiple sclerosis and rheumatoid arthritis. Cyxone's head office is located in Malmö. 

Cyxone

The subscription period in Cyxone AB's ("Cyxone" or the "Company") rights issue ended on 15 August 2024 (the "Rights Issue"). The Rights Issue was subscribed to a total of approximately 27.3...

<div class="abstract">The subscription period in Cyxone AB's ("Cyxone" or the "Company") rights issue ended on 15 August 2024 (the "Rights Issue"). The Rights Issue was subscribed to a total of approximately 27.3 percent, including pre-subscription commitments. Cyxone will thus be provided proceeds of approximately SEK 6.3 million before deduction of transaction related costs.</div>Subscription, allocation and paymentThe Rights Issue was subscribed to approximately SEK 6.3 million including pre-subscription commitments of approximately SEK 0.26 million, which corresponds to a subscription rate of approximately 27.3 percent. Cyxone is thus provided approximately SEK 6.3 million before transaction related costs.A total of 150,815,096 shares were subscribed for with the support of pre-emptive subscription rights, including pre-subscription commitments. In total, 6,631,167 shares were subscribed without the support of pre-emptive subscription rights. Through the Rights Issue, 157,446,263 new shares will thus be issued. The subscribers who are allocated shares without preferential rights will receive settlement notes, which are planned to be sent out today, after a formal board decision on allocation. Allotted shares without pre-emptive right shall be paid in accordance with the instructions on the settlement note.Number of shares and share capitalWhen the Rights Issue has been registered with the Swedish Companies Registration Office, the total number of shares will have increased by 157,446,263 shares, from 215,926,036 shares to 373,372,299 shares, and the Company's share capital will upon registration, have increased by SEK 6,297,850.52, from SEK 8,637,041.44 to SEK 14,934,891.96. The shareholders who have not participated in the Rights Issue will be subject to a dilution effect corresponding to approximately 42.2 percent of the votes and capital.Trading in BTATrading in BTA's will take place on Nasdaq First North Growth Market until after the Rights Issue has been registered with the Swedish Companies Registration Office. The registration is expected to take place around 30 August 2024.AdvisorsIn connection with the Rights Issue, Sedermera Corporate Finance AB assists the Company with project management, Markets &amp; Corporate Law Nordic AB with legal advice and Hagberg &amp; Aneborn Fondkommission AB with issuing services.For more information about the Rights Issue, please contact:Sedermera Corporate Finance AB Phone: +46 (0)40 615 14 10 E-mail: cf@sedermera.se www.sedermera.seFor more information about the Company, please contact:Kjell Stenberg, CEO Phone: +46 (0)70 781 88 08 E-mail: kjell.g.stenberg@cyxone.com www.cyxone.comAbout CyxoneCyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit www.cyxone.com

Stay up to date with our newsletter